Examkin

Soru

Zorluk: OrtaClinical Preventive Services and Screening

A 7-year-old girl is evaluated in the primary care clinic for a health maintenance examination before starting the second grade. She has a history of polyarticular juvenile idiopathic arthritis, which was diagnosed two years ago. Her symptoms are currently well controlled on a regimen of methotrexate and adalimumab (a tumor necrosis factor-alpha inhibitor). Review of the patient's vaccination record indicates that she received all routine immunizations during infancy. However, she missed her kindergarten boosters typically given between 4 and 6 years of age, including the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine, inactivated poliovirus vaccine (IPV), measles, mumps, and rubella (MMR) vaccine, and varicella vaccine. The patient's father requests that she receive all necessary vaccinations today to meet school requirements. Which of the following is the most appropriate next step in preventive care for this patient?

  1. A
    Administer the DTaP, IPV, MMR, and varicella vaccines
  2. Administer the DTaP and IPV vaccines, and withhold the MMR and varicella vaccinesCevap
  3. C
    Administer the DTaP and IPV vaccines, and schedule the MMR and varicella vaccines for 4 weeks later
  4. D
    Withhold the DTaP, IPV, MMR, and varicella vaccines due to immunosuppression
  5. E
    Administer the MMR and varicella vaccines, and withhold the DTaP and IPV vaccines

Cevap

Administer the DTaP and IPV vaccines, and withhold the MMR and varicella vaccines
The correct action is to administer the inactivated vaccines (DTaP and IPV) and withhold the live-attenuated vaccines (MMR and varicella). This patient has polyarticular juvenile idiopathic arthritis treated with adalimumab, a tumor necrosis factor-alpha (TNF-alpha) inhibitor. Biologic agents like adalimumab cause profound systemic immunosuppression. In patients receiving such therapies, the administration of live-attenuated vaccines is strictly contraindicated because the attenuated viruses can replicate unchecked, leading to severe or life-threatening vaccine-strain infections. Therefore, the MMR and varicella vaccines must be withheld. However, inactivated vaccines, toxoids, and recombinant vaccines (such as DTaP and IPV) cannot replicate and do not pose an infectious risk. They are safe and highly recommended for immunocompromised patients, who are often at higher risk for severe complications from vaccine-preventable diseases. The DTaP and IPV vaccines should be administered at this visit to ensure the patient is protected.

Adım Adım Çözüm

1
Identify the patient's current immune status.
The patient is taking adalimumab, a TNF-alpha inhibitor, which causes significant systemic immunosuppression.
To determine if there are any contraindications to standard medical interventions and preventive care.
2
Categorize the due vaccines by their formulation type.
DTaP and IPV are inactivated/toxoid vaccines. MMR and varicella are live-attenuated vaccines.
Different vaccine formulations have specific safety profiles in immunosuppressed patients.
3
Apply standard immunization guidelines for immunosuppressed individuals.
Inactivated vaccines should be administered to maintain immunity, while live-attenuated vaccines must be withheld due to the risk of vaccine-strain infection.
To select the appropriate management plan that protects the patient without causing iatrogenic harm.

Anahtar Kavram

Live-attenuated vaccines (e.g., MMR, varicella) are strictly contraindicated in patients receiving biologic immunosuppressive therapy, whereas inactivated vaccines (e.g., DTaP, IPV) are safe and highly recommended.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Clinical Preventive Services and Screening

Bu konudan daha fazla soru